Compare PPG Industries, Inc. (PPG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs TransMedics Group Inc — how do they compare? PPG Industries, Inc. trades at $104.77 (market cap $23.44B), while TransMedics Group Inc trades at $77.54 (market cap $2.74B). The key difference: PPG Industries, Inc. is far larger — about 8.6× TransMedics Group Inc's market cap, and PPG Industries, Inc. pays a 2.81% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and TransMedics Group Inc for 24 Days on average.
| PPG | TMDX | |
|---|---|---|
Market Cap | $23.44B | $2.74B |
Volume | 2,064,777 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $150.42 |
52-Week Low | $94.34 | $61.99 |
Typical Hold Time | 68 Days | 24 Days |
Enterprise Value | $29.31B | $3.13B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG trades at $105.08, down 1.37% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, with a Q2 2026 EPS miss of $2.23 vs. $2.25 expected, though Q1 2026 beat expectations. Fundamentals show a P/E of 15.13, net income margin of 9.57%, and strong cash flow from operations of $1.94B in 2025. Recent news highlights margin pressures in the Automotive Refinish segment but innovation efforts in marine coatings.
The outlook is cautiously optimistic, with a consensus price target of $130 implying 24% upside, supported by 55% analyst buy ratings. Risks include segment-specific weakness and macroeconomic headwinds, but valuation remains reasonable with solid profitability. The stock offers a dividend yield from its upcoming $0.74 payout, appealing for income-focused investors amid ongoing cost management initiatives.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
